Sotorasib丨CAS 2252403-56-6

Sotorasib is a targeted small-molecule inhibitor used in pharmaceutical and clinical research for the treatment of cancers driven by KRAS G12C mutations. It is primarily applied in oncology for non-small cell lung cancer (NSCLC), colorectal cancer, and other solid tumors harboring this specific KRAS mutation. The compound functions by selectively and irreversibly binding to the mutant KRAS G12C protein, locking it in an inactive state, and thereby inhibiting downstream signaling pathways that promote tumor growth and proliferation. Sotorasib is also utilized in preclinical and translational studies to explore combination therapies with immunotherapy, chemotherapy, or other targeted agents, and to understand mechanisms of resistance to KRAS inhibition.

The benefits of Sotorasib include its high selectivity for the KRAS G12C mutant over wild-type KRAS, reducing off-target effects and improving the safety profile. Its covalent and irreversible binding provides sustained inhibition of oncogenic signaling, which can lead to durable tumor responses. Sotorasib's oral bioavailability allows convenient administration in clinical settings. Additionally, its targeted mechanism enables personalized therapy for patients with KRAS G12C-positive tumors, offering a precision medicine approach that improves efficacy while minimizing systemic toxicity. The compound also provides a valuable tool for studying KRAS biology and the development of next-generation targeted therapies.